Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
Returns on capital
Pelthos Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-111.4%
avg 60.4%
ROIC
-26.4%
avg 268.9%
ROA
-33.2%
avg -2122.6%
Analysis
ROIC is currently the strongest return metric at -26.4% versus its period average of 268.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
John Gay | CFO, Treasurer & Secretary | USD 744.2K | 50 | — | — |
Scott Plesha | Chief Executive Officer, President & Director | USD 685.67K | 61 | — | — |
Sai Rangarao | Chief Commercial Officer | USD 579.36K | 42 | 30.52K | 0.88% |
Compensation is shown in the reported currency; data updated Oct 17, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 2, 2025.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$999,983.28
Sells
24
$486,272.21
Net Transaction Value
+$513,711.07
Net buying
Most Active
Friedberg Ezra M
11 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 2, 26Oct 2, 2026 | Friedberg Ezra M Direct | Sell | $11.6K$11,560.03 |
| Oct 2, 26Oct 2, 2026 | Pauls Matthew Direct | Sell | $16.5K$16,506.00 |
| Oct 2, 26Oct 2, 2026 | Greenleaf Peter Direct | Sell | $16.9K$16,872.49 |
| Jul 2, 26Jul 2, 2026 | Pauls Matthew Direct | Sell | $18K$17,989.16 |
| Jul 2, 26Jul 2, 2026 | Pauls Matthew Direct | Sell | $2.6K$2,571.88 |
| Jul 2, 26Jul 2, 2026 | Greenleaf Peter Direct | Sell | $18.5K$18,508.72 |
| Jul 2, 26Jul 2, 2026 | Greenleaf Peter Direct | Sell | $2.3K$2,318.23 |
| Jul 2, 26Jul 2, 2026 | Friedberg Ezra M Direct | Sell | $13.9K$13,900.18 |
| Jul 2, 26Jul 2, 2026 | Friedberg Ezra M Direct | Sell | $655.8$655.81 |
| Jun 15, 26Jun 15, 2026 | Friedberg Ezra M Direct | Sell | $1.6K$1,648.48 |
1–10 of 26
Summary
Insiders reported 2 buys worth $999,983.28 and 24 sells worth $486,272.21 over the last 12 months. That adds up to net buying of $513,711.07. Friedberg Ezra M was the most active insider with 11 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +71.5% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +71.5% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Pelthos Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PTHS's management, answered from reported figures.
Who manages PTHS?
Pelthos Therapeutics Inc. (PTHS) lists 3 active executives. The top listed executive is John Gay, CFO, Treasurer & Secretary.
Are PTHS insiders buying or selling?
Recent insider activity shows net buying of $46.59M.
Continue the stock analysis
Jump to another research area for this company.